Corporate ActionAug 13, 2026, 05:45 PM
BridgeBio: KKR Sells 5M Shares in Secondary Offering
AI Summary
BridgeBio Pharma, Inc. announced a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The company itself is not selling any shares and will not receive any proceeds from this offering. The proposed offering is subject to market and other conditions, with William Blair, Goldman Sachs & Co. LLC, and KKR acting as joint book-running managers.
Key Highlights
- Secondary public offering of 5,000,000 shares of common stock announced.
- Selling stockholder is KKR Genetic Disorder L.P.
- BridgeBio Pharma will not sell shares or receive any proceeds from the offering.
- William Blair, Goldman Sachs & Co. LLC, and KKR are joint book-running managers.
- Offering is pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-297701).
- Registration statement became effective upon filing on July 24, 2026.
Price Impact
More from BBIO